Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Crain's Chicago Business2d
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
SEARL Clarifies Reports of Acquiring Majority Stake in Abbott Laboratories
The Searle Company Limited (PSX: SEARL) has denied showing any interest in acquiring a 51 percent stake in Abbott ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...